Skip to main content

Table 1 Baseline characteristics (n = 3421)

From: Leukocyte count and the risk of adverse outcomes in patients with HFpEF

Characteristic

Leukocyte count

5.5 n = 753

5.5–6.7 n = 707

6.7–8.0 n = 720

 > 8.0 n = 718

p-value

Age, mean ± SD, years

69 ± 9.2

69 ± 9.7

69 ± 10

69 ± 9

0.867

Male (%)

289 (38)

304 (43)

362 (50)

372 (52)

0.000

Race

    

0.620

White (%)

671 (89)

629 (89)

641 (89)

629 (88)

 

Black (%)

69 (9)

58 (8)

63 (9)

66 (9)

 

Other (%)

13 (2)

20 (2)

16 (2)

23 (3)

 

Smoker (%)

237 (32)

241 (34)

267 (37)

306 (43)

0.001

Hypertension (%)

685 (91)

645 (91)

673 (94)

673 (94)

0.077

Dyslipidemia (%)

431 (57)

406 (57)

423 (59)

483 (67)

0.000

Previous myocardial infarction (%)

143 (19)

154 (22)

173 (24)

192 (27)

0.004

Prior heart failure hospitalization (%)

562 (75)

511 (72)

520 (72)

504 (70)

0.304

Angina pectoris (%)

340 (45)

347 (49)

345 (48)

311 (43)

0.112

PCI (%)

89 (12)

87 (12)

97 (14)

132 (19)

0.000

CABG (%)

75 (10)

80 (11)

85 (12)

113 (16)

0.006

Diabetes mellitus (%)

198 (26)

198 (28)

244 (34)

318 (44)

0.000

Atrial fibrillation (%)

262 (35)

218 (31)

239 (33)

280 (39)

0.011

COPD (%)

58 (8)

67 (10)

89 (12)

124 (17)

0.000

Asthma (%)

36 (5)

56 (8)

43 (6)

61 (9)

0.016

Stroke (%)

56 (7)

43 (6)

59 (8)

68 (10)

0.112

Peripheral arterial disease (%)

49 (7)

55 (8)

66 (9)

89 (12)

0.000

Thyroid disease (%)

128 (17)

105 (15)

104 (15)

143 (20)

0.021

Pacemaker implanted (%)

64 (9)

50 (7)

56 (8)

61 (9)

0.713

ICD (%)

10 (1.3)

8 (1.1)

8 (1.1)

12 (1.7)

0.773

HR (b.p.m.)

69 ± 10.1

68 ± 9.9

68 ± 11.1

70 ± 11.3

0.078

Systolic blood pressure, mean ± SD, mmHg

129 ± 12.6

130 ± 13.9

130 ± 14.6

129 ± 14.9

0.110

Diastolic blood pressure

76 ± 10.4

77 ± 10.6

76 ± 10.8

74 ± 11.1

0.000

Body mass index, mean ± SD, kg/m2

31 ± 6.6

32 ± 6.5

32 ± 7.1

34 ± 7.9

0.000

eGFR (mL/min)

67 ± 18.2

69 ± 22.5

68 ± 19.8

65 ± 20.1

0.002

BUN (mg/dL)

16.5 (6.8,22.1)

16.2 (5.0,22.4)

16.5 (5.6,23.0)

17.6 (8.1,26.0)

0.004

Hematocrit (%)

39 ± 5.0

40 ± 4.8

40 ± 5.4

41 ± 5.7

0.000

Hemoglobin (g/dL)

12.9 (12.0,14.0)

13.2 (12.2,14.3)

13.4 (12.3,14.5)

13.5 (12.2,14.8)

0.000

Platelet (k/uL)

207 (173,243)

220 (188,254)

223 (193,264)

245 (208,294)

0.000

Albumin (g/dL)

3.9 ± 2.5

3.8 ± 2.7

3.7 ± 2.5

3.7 ± 2.8

0.000

logBNP

2.6 ± 0.5

2.6 ± 0.5

2.6 ± 0.5

2.6 ± 0.5

0.627

LVEF (%)

59 ± 6.5

59 ± 6.9

59 ± 6.0

59 ± 6.7

0.076

New York Heart Association class III-IV (%)

514 (68)

509 (72)

501 (70)

428 (60)

0.000

Aspirin use (%)

453 (60)

458 (65)

475 (66)

458 (64)

0.110

b-blockers (%)

573 (76)

555 (79)

565 (79)

551 (78)

0.599

ACEi (%)

504 (66)

455 (64)

455 (63)

438 (61)

0.120

ARB (%)

107 (14)

113 (16)

109 (15)

132 (18)

0.155

Statins (%)

334 (44)

332 (47)

362 (50)

426 (59)

0.000

Calcium channel blockers (%)

276 (37)

292 (41)

272 (38)

281 (39)

0.300

Spironolactone (%)

361 (48)

370 (52)

346 (48)

378 (53)

0.118

Loop diuretic (%)

326 (43)

329 (47)

349 (49)

458 (64)

0.000

Thiazide diuretic (%)

322 (43)

278 (39)

286 (40)

216 (30)

0.000

  1. Values are presented as mean ± SD or median (25th-75th percentile) for continuous variables and number (%) for categorical variables. Statistical significance for continuous data was tested using the analysis of variance procedure and categorical data was tested using the χ2test
  2. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; ICD, Implantable Cardioverter Defibrillator; COPD, chronic obstructive pulmonary disease; CABG, Coronary Artery Bypass Grafting;PCI, percutaneous coronary intervention;DBP,diastolic blood pressure; eGFR, estimated glomerular filtration rate; HR, heart rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SBP, systolic blood pressure
  3. eGFR by the Chronic Kidney Disease Epidemiology Collaboration formula